Decernotinib |
|
Synonyms: (R)-2-((2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide;VX-509, VX509, VX 509, VRT-831509, VRT831509, VRT 831509; | |
Cat. No.: D15000 | CAS No.: 944842-54-0 |
MDL.: | Formula: C18H19F3N6O |
F.W.329.38 | Purity: 99% |
Storage: | |
  |
Catalog Number: | D15000 | CAS No.: | 944842-54-0 | |
MDL: | Formula: | C18H19F3N6O | ||
F.W.: | 329.38 | Purity: | 99% | |
Package: | Unit: | mg | ||
Appearance: | M.P.: | |||
B.P.: | Density: | |||
Optical Rotation: | Refractive Index: | |||
Solubility: | DMSO | Stability: | ||
Storage: | Category: | Reference Standard | ||
Reference: | Luc J. Farmer et. al., J. Med. Chem., 2015, 58 (18), pp 7195–7216 | |||
Application: | Decernotinib is an oral, selective Janus kinase 3 (JAK3) inhibitor being developed by Vertex | |||
Category: | Heterocycles, Nucleotides, Bases & Related Reagents, Pharmaceuticals, Intermediates & Fine Chemicals, |